• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体激动剂与普伐他汀联合治疗能否减轻糖尿病诱导的实验性肾病的发病？

Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?

作者信息

Gad Hayam I

机构信息

Physiology Department, College of Medicine, King Saud University, PO 2925 (29), Riyadh 11461, Kingdom of Saudi Arabia. Tel. +966 (11) 8052154 / 8050193. Fax. +966 (11) 8054684. E-mail.

出版信息

Saudi Med J. 2014 Nov;35(11):1339-47.

PMID:25399210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4362144/
Abstract

OBJECTIVES

To investigate the combined effects of rosiglitazone and pravastatin on renal functions in early streptozotocin induced diabetic nephropathy (DN).

METHODS

This study was carried out at King Khalid University Hospital Animal House, Riyadh, Saudi Arabia from August 2013 to February 2014. Fifty male Wistar rats were assigned to normal control rats and diabetic rats that received saline, rosiglitazone, pravastatin, or rosiglitazone+pravastatin for 2 months. Their weight range was 230-250 gm, and age range was from 18-20 weeks. At the end of experiment, creatinine clearance, and urinary albumin to creatinine ratio (ACR) were measured. Blood samples were analyzed for transferrin, glycosylated hemoglobin (HbA1c), lipid profile, tumor necrosis factor-alpha (TNF-α), intercellular adhesion molecule-1 (ICAM-1), and lipid peroxide.

RESULTS

Rosiglitazone treatment increased creatinine clearance and plasma transferrin, and decreased urinary ACR, HbA1c, plasma TNF-α, ICAM-1, and serum lipid peroxide levels without affecting the altered lipid profile. Pravastatin treatment produced similar results and normalized the lipid alteration. The combination of rosiglitazone and pravastatin was more effective in attenuating the diabetes-induced nephropathy compared with treatment with either drug alone.

CONCLUSION

The combination strategy of rosiglitazone and pravastatin may provide a potential synergistic renoprotective effect against DN by improving renal functions and reducing indices of DN.

摘要

目的

研究罗格列酮和普伐他汀联合应用对链脲佐菌素诱导的早期糖尿病肾病（DN）大鼠肾功能的影响。

方法

本研究于2013年8月至2014年2月在沙特阿拉伯利雅得国王哈立德大学医院动物房进行。将50只雄性Wistar大鼠分为正常对照组和糖尿病组，糖尿病组大鼠分别给予生理盐水、罗格列酮、普伐他汀或罗格列酮+普伐他汀，持续给药2个月。大鼠体重范围为230 - 250克，年龄范围为18 - 20周。实验结束时，测量肌酐清除率和尿白蛋白肌酐比值（ACR）。对血样进行转铁蛋白、糖化血红蛋白（HbA1c）、血脂谱、肿瘤坏死因子-α（TNF-α）、细胞间黏附分子-1（ICAM-1）和脂质过氧化物分析。

结果

罗格列酮治疗可增加肌酐清除率和血浆转铁蛋白，降低尿ACR、HbA1c、血浆TNF-α、ICAM-1和血清脂质过氧化物水平，且不影响血脂谱的改变。普伐他汀治疗产生了类似的结果，并使血脂改变恢复正常。与单独使用任一药物相比，罗格列酮和普伐他汀联合应用在减轻糖尿病诱导的肾病方面更有效。

结论

罗格列酮和普伐他汀联合应用策略可能通过改善肾功能和降低糖尿病肾病指标，对糖尿病肾病提供潜在的协同肾脏保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/f1edf926d986/SaudiMedJ-35-1339-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/c8ff40ceea30/SaudiMedJ-35-1339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/f0b8d399203c/SaudiMedJ-35-1339-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/829660c210c0/SaudiMedJ-35-1339-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/7cdd6cbaa07c/SaudiMedJ-35-1339-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/f1edf926d986/SaudiMedJ-35-1339-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/c8ff40ceea30/SaudiMedJ-35-1339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/f0b8d399203c/SaudiMedJ-35-1339-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/829660c210c0/SaudiMedJ-35-1339-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/7cdd6cbaa07c/SaudiMedJ-35-1339-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/4362144/f1edf926d986/SaudiMedJ-35-1339-g008.jpg

相似文献

1
Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?过氧化物酶体增殖物激活受体激动剂与普伐他汀联合治疗能否减轻糖尿病诱导的实验性肾病的发病？
Saudi Med J. 2014 Nov;35(11):1339-47.
2
Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.罗格列酮通过抑制链脲佐菌素诱导的糖尿病大鼠肾细胞间黏附分子-1表达发挥肾脏保护作用。
J Endocrinol Invest. 2008 Dec;31(12):1069-74. doi: 10.1007/BF03345654.
3
Effects of pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of diabetic nephropathy in an experimental model of diabetic renal disease.普伐他汀或12/15脂氧合酶途径抑制剂对糖尿病肾病实验模型中糖尿病肾病指标的影响。
Saudi Med J. 2012 Jun;33(6):608-16.
4
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.非诺贝特与罗格列酮的低剂量联合可阻止糖尿病诱导的实验性肾病的进展。
Eur J Pharmacol. 2010 Jun 25;636(1-3):137-44. doi: 10.1016/j.ejphar.2010.03.002. Epub 2010 Mar 27.
5
Black mulberry fruit extract alleviates streptozotocin-induced diabetic nephropathy in rats: targeting TNF-α inflammatory pathway.黑桑椹果提取物通过靶向 TNF-α 炎症途径缓解链脲佐菌素诱导的大鼠糖尿病肾病。
J Pharm Pharmacol. 2020 Nov;72(11):1615-1628. doi: 10.1111/jphp.13338. Epub 2020 Aug 5.
6
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.过氧化物酶体增殖物激活受体γ激动剂罗格列酮可预防实验性糖尿病中的蛋白尿，但不能预防肾小球硬化。
Am J Nephrol. 2010;32(5):393-402. doi: 10.1159/000320129. Epub 2010 Sep 3.
7
Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.辅酶Q10单独及与二甲双胍联合应用对链脲佐菌素-烟酰胺诱导的大鼠糖尿病肾病的影响。
Indian J Pharmacol. 2014 Nov-Dec;46(6):627-32. doi: 10.4103/0253-7613.144924.
8
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists.糖尿病中肾α(1D)-肾上腺素能受体表达谱的改变及其受PPAR激动剂的调节
J Diabetes Res. 2014;2014:725634. doi: 10.1155/2014/725634. Epub 2014 Mar 17.
9
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.罗格列酮通过降低链脲佐菌素诱导的糖尿病大鼠肾脏中 Chemerin 和 ChemR23 的表达来改善糖尿病肾病。
Inflammation. 2012 Aug;35(4):1287-93. doi: 10.1007/s10753-012-9440-y.
10
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.罗格列酮可降低氧化损伤的肾脏和血浆标志物，并在改善糖尿病肾病过程中逆转尿液代谢物异常。
Am J Physiol Renal Physiol. 2008 Oct;295(4):F1071-81. doi: 10.1152/ajprenal.90208.2008. Epub 2008 Jul 30.

引用本文的文献

1
Optimizing diabetic kidney disease animal models: Insights from a meta-analytic approach.优化糖尿病肾病动物模型：荟萃分析方法的启示。
Animal Model Exp Med. 2023 Oct;6(5):433-451. doi: 10.1002/ame2.12350. Epub 2023 Sep 18.
2
Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats.普伐他汀对阿霉素诱导的大鼠肾病的影响。
Iran J Pharm Res. 2018 Fall;17(4):1413-1419.

本文引用的文献

1
Selective inhibition of NADPH oxidase reverses the over contraction of diabetic rat aorta.NADPH氧化酶的选择性抑制可逆转糖尿病大鼠主动脉的过度收缩。
Redox Biol. 2014;2:61-4. doi: 10.1016/j.redox.2013.12.002. Epub 2013 Dec 11.
2
Physiological functions of peroxisome proliferator-activated receptor β.过氧化物酶体增殖物激活受体 β 的生理功能。
Physiol Rev. 2014 Jul;94(3):795-858. doi: 10.1152/physrev.00027.2013.
3
New insights into the use of biomarkers of diabetic nephropathy.糖尿病肾病生物标志物应用的新见解。
Adv Chronic Kidney Dis. 2014 May;21(3):318-26. doi: 10.1053/j.ackd.2014.03.008.
4
Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis.比较过氧化物酶体增殖物激活受体γ激动剂罗格列酮和曲格列酮在实验性结肠炎预防治疗中的抗炎作用。
J Physiol Pharmacol. 2013 Oct;64(5):587-95.
5
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.过氧化物酶体增殖物激活受体的体内作用：血糖控制、胰岛素敏感性及胰岛素分泌。
Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S162-74. doi: 10.2337/dcS13-2003.
6
Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats.罗格列酮/吡格列酮与格列美脲联合治疗实验性诱导的2型糖尿病大鼠糖尿病肾病
J Biomed Res. 2011 Nov;25(6):411-7. doi: 10.1016/S1674-8301(11)60054-7.
7
Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy.细胞间黏附分子 1（ICAM1）与糖尿病和糖尿病肾病的关系。
Front Endocrinol (Lausanne). 2013 Jan 22;3:179. doi: 10.3389/fendo.2012.00179. eCollection 2012.
8
Mechanisms of diabetic complications.糖尿病并发症的发病机制。
Physiol Rev. 2013 Jan;93(1):137-88. doi: 10.1152/physrev.00045.2011.
9
Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.间充质干细胞改善 1 型糖尿病肾病大鼠模型的足细胞损伤和蛋白尿。
Biol Blood Marrow Transplant. 2013 Apr;19(4):538-46. doi: 10.1016/j.bbmt.2013.01.001. Epub 2013 Jan 4.
10
Estimating glomerular filtration rate from serum creatinine and cystatin C.基于血清肌酐和胱抑素 C 估算肾小球滤过率。
N Engl J Med. 2012 Jul 5;367(1):20-9. doi: 10.1056/NEJMoa1114248.